Skip to main content

Medical Policy Revision: Histone Deacetylase Inhibitor(s) [Romidepsin (Istodax®)]

Effective June 24, 2019, Horizon BCBSNJ will change the way we consider certain professional claims based on revisions to our medical policy, Histone Deacetylase Inhibitor(s) [Romidepsin (Istodax®)].

Access our Medical Policy Manual to review this medical policy content.¹


Claims submitted for services provided on and after June 24, 2019 to patients enrolled in Horizon BCBSNJ commercial, Administrative Services Only (ASO) or Medicare Advantage (MA) plans will be processed as follows.

For services provided to patients 18 years of age or older:

  • Based on the submitted diagnosis code(s), information may be requested to help us determine the medical appropriateness of the administration of drugs represented by HCPCS code J9315. Following our review of medical record information, the code above may be denied as an experimental/investigational, non-covered service.

For services provided to patients under 18 years of age:

  • Regardless of the submitted diagnosis code(s), the administration of drugs represented by HCPCS code J9315 will be denied as an experimental/investigational, non-covered service.

Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been canceled or postponed, the changes will be applied to claims for dates of service on and after June 24, 2019.

¹ The content of Horizon BCBSNJ medical policies that apply to Horizon BCBSNJ MA plans may include reference to pertinent National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs). We follow Centers for Medicare & Medicaid Services (CMS) guidelines, NCDs and/or LCDs in our processing of claims for services provided to our MA members. For those services where no LCD or NCD exists, claims for MA members will be processed based on our policy guidelines.

Published on: March 25, 2019, 15:11 p.m. ET
Last updated on: March 25, 2019, 15:12 p.m. ET